Literature DB >> 2033426

Is more better? Dose intensity in neuroblastoma.

J R Anderson, P F Coccia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2033426     DOI： 10.1200/JCO.1991.9.6.902

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  Pilot study of cisplatin, etoposide, bleomycin, and escalating dose cyclophosphamide therapy for children with high risk germ cell tumors: a report of the children's oncology group (COG).

Authors:  Marcio H Malogolowkin; Mark Krailo; Neyssa Marina; Thomas Olson; A Lindsay Frazier
Journal:  Pediatr Blood Cancer       Date:  2013-05-23       Impact factor: 3.167

Review 2.  Cellular immunotherapy for neuroblastoma: a review of current vaccine and adoptive T cell therapeutics.

Authors:  C U Louis; M K Brenner
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

3.  Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells. Potential for residual disease eradication.

Authors:  N K Foreman; D R Rill; E Coustan-Smith; E C Douglass; M K Brenner
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.